Peter Drucker Society Europe Appoints Sunil Prashara of Project Management Institute to International Advisory Board
1.4.2021 18:00:00 EEST | Business Wire | Press release
Project Management Institute (PMI) and the Peter Drucker Society Europe today announced the launch of a strategic partnership in which PMI President and CEO Sunil Prashara will join the Drucker Society International Advisory Board.
The Peter Drucker Society Europe is a non-profit organization that seeks to advance a critical, international dialogue between management practitioners, academics, and other stakeholders. Their mission is to give a new voice to management in all sectors of society, thus contributing to the continuous improvement of the practice of management. This partnership will complement PMI’s role as the world's leading association for project professionals and changemakers.
“Both organizations are non-profit entities with the shared objective of improving the practice of management in every area of society, from government and public sector to private and not-for-profit bodies,” said Richard Straub, founder and president of the Global Peter Drucker Forum, the annual conference organized by the Drucker Society Europe.
“We are enabling millions of project leaders and changemakers to make important contributions to the world,” Prashara said. “PMI’s mission—to enable individuals to make ideas reality—aligns perfectly with Peter Drucker’s legacy of rigorous thought leadership around management as a systematic discipline entailing research, teaching, and practice. I see the Drucker Forum as a key platform and partner for raising awareness of the fundamental importance of management in building functioning modern societies.”
In support of their mission, the Peter Drucker Society Europe has designated the Global Peter Drucker Forum as a strategic initiative. The forum is an international management conference held annually in Peter Drucker's home city of Vienna, Austria, and is often hailed as the "Davos of Management,” as it has become one of the leading management conferences in Europe. The Global Peter Drucker Forum 2021 is centered on the theme of “The Human Imperative: Navigating Uncertainty in the Digital Age.” Forum stakeholders will take part in a range of discussion on ways to resolve tensions between technocratic and humanistic approaches to crisis, to arrive at a synthesis of "change and continuity."
###
About Project Management Institute
Project Management Institute (PMI) is the world's leading professional association for a growing global community of millions of project professionals and changemakers worldwide.
As the world’s leading authority on project management, PMI empowers people to make ideas a reality. Through global advocacy, networking, collaboration, research, and education. PMI prepares organizations and individuals at every stage of their career journey to work smarter so they can drive success in a world of change.
Building on a proud legacy dating to 1969, PMI is a “for-purpose” organization working in nearly every country around the world to advance careers, strengthen organizational success, and enable changemakers with new skills and ways of working to maximize their impact. PMI offerings include globally recognized standards, certifications, online courses, thought leadership, tools, digital publications, and communities.
Visit us at https://www.pmi.org/, www.projectmanagement.com , https://www.linkedin.com/company/pminstitute , www.facebook.com/PMInstitute , and on Twitter.
About Peter Drucker Society Europe Initiative
The Peter Drucker Society Europe is a practitioner-led, multi-stakeholder group that builds on Peter Drucker’s fundamental ideas and ideals with the aim of contributing to the evolution of management as a vital piece of a functioning modern society. Each year, the Drucker Society Europe hosts the Global Peter Drucker Forum, a crystallizing event where decision makers convene to discuss the future of management in a pragmatic and solution-oriented manner.
To fulfil its mission, the Peter Drucker Society Europe has established legally and financially independent nonprofit Drucker Society chapters in Austria, London, Barcelona and Mannheim. Please note that The Drucker 1996 Literary Works Trust is the owner of the service marks "Peter Drucker", "Peter F. Drucker" and "Drucker".
Learn more at www.druckerforum.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005059/en/
Contact information
PMI Contact:
David Summers | mobile:(610) 930-3425
press@pmi.org
Drucker Forum Contact:
www.druckerforum.org/contact/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom